|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||100.00 - 101.72|
|52-week range||62.74 - 105.68|
|Beta (5Y monthly)||0.20|
|PE ratio (TTM)||0.33|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Three Motley Fool contributors believe they've identified such exceptions. Here's why they think Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer growth stocks to buy in December. David Jagielski (Eli Lilly): Eli Lilly is becoming a beast in the healthcare industry.
Artificial intelligence has undoubtedly been the hottest investing topic on Wall Street this year. Led by such products as Wegovy, manufactured by Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), the area of obesity care is garnering substantial attention. One of Novo Nordisk's strengths is its focus on diabetes and obesity care.
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.